CLINICAL TRIALS
Click below to learn more about current Vical clinical trials for specific cancer and infectious disease applications.
INVESTOR INFO
| NASDAQ: VICL | |
WELCOME TO VICAL
Vical researches and develops biopharmaceutical products based on our patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Our independent programs include the Allovectin-7® immunotherapy for metastatic melanoma, the vaccine to prevent cytomegalovirus reactivation in hematopoietic stem cell transplant patients, and vaccines for pandemic influenza.
VAXFECTIN®
Vical's proprietary Vaxfectin® adjuvant for vaccines has demonstrated safety and effectiveness in a number of animal models and was successfully tested in a Phase 1 human trial against H5N1 pandemic influenza. References to published data are included in the Vaxfectin® Publications page.